Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
Platform foR European Preparedness Against (Re-)emerging Epidemics (PREPARE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,Netherlands,United Kingdom,Netherlands,Switzerland,Netherlands,United Kingdom,United Kingdom,Spain,France,Croatia,Ireland,Belgium,Germany,Belgium,France,Germany,Italy,Australia,Belgium,Germany,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2021-01-31
Duration (months): 84.0
Total project cost (EUR): 31130188.0
EU funding (EUR): 23992375.0
Participants: 31
Project status: CLOSED

Far from receding, the threats posed by infections with epidemic potential grow ever greater. Although Europe has amongst the best healthcare systems in the world, and also the world’s supreme researchers in this field, we lack co-ordination and linkage between networks that is required to respond fast to new threats. This consortium of consortia will streamline our response, using primary and secondary healthcare to detect cases with pandemic potential and to activate dynamic rapid investigation teams that will deploy shared resources across Europe to mitigate the impact of future pandemics on European health, infrastructure and economic integrity. If funded, PREPARE will transform Europe’s response to future severe epidemics or pandemics by providing infrastructure, co-ordination and integration of existing clinical research networks, both in community and hospital settings. It represents a new model of collaboration and will provide a one-stop shop for policy makers, public health agencies, regulators and funders of research into pathogens with epidemic potential. It will do this by mounting interepidemic (‘peace time’) patient oriented clinical trials in children and in adults, investigations of the pathogenesis of relevant infectious diseases and facilitate the development of sophisticated state-of-the-art near-patient diagnostics. We will develop pre-emptive solutions to ethical, administrative, regulatory and logistical bottlenecks that prevent a rapid response in the face of new threats. We will provide education and training not only to the members of the network, but also to external opinion leaders, funders and policy makers thereby streamlining our future response. By strengthening and integrating interepidemic research networks, PREPARE will enable the rapid coordinated deployment of Europe’s elite clinical investigators, resulting in a highly effective response to future outbreaks based on solid scientific advances.

Keywords: clinical research,epidemics,infectious diseases,pan-european network,clinical management,point of care diagnostics
Roadmap for Research and Innovation in Health Technology (ITECH)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Coordination and support actions
Countries involved: France,Greece,Finland,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2016-02-29
Duration (months): 30.0
Total project cost (EUR): 545671.6
EU funding (EUR): 499999.0
Participants: 4
Project status: CLOSED

Research and innovation in Health Technologies continuously deliver new products, devices and services. The “idea to market” process is complex due to multiple actors, institutional bodies and operators. The ITECH project aims at defining a strategy plan in Health Technologies to contribute to the Horizon 2020 Common EU Strategic Framework for Research and Innovation. The Support Action will gather EU and national networks or experts, representative of researchers, physicians, companies and health organizations. The key issue is: “What is the best strategy to optimize research & innovation and translate research into successful Health Technology products and services?” ITECH is an opportunity for identifying throughout Europe gaps and barriers currently existing at all stages of the “idea to market” process and to propose a strategy to accelerate and support this process. The objectives are: 1: To map existing national and European instruments supporting research & innovation and the “idea-to-market” strategy; identify the similarities and dissimilarities between countries 2: To build and validate a model describing the phases of maturation of innovation 3: To identify, from this model, gaps and barriers currently existing at all stages 4: To propose solutions to overcome the identified gaps and barriers 5: To find the best schemes for promoting synergies and collaborations with existing actions 6: To road map the areas where European research and industry can take a worldwide leadership role 7: To disseminate the outcomes of the project to all actors involved in the process “idea-to-market”. The ultimate goal is therefore to build a perennial network of referents in Healthcare Technologies integrating the experience of 27 European contact nodes and to propose to decision makers a strategy plan for the Development of Healthcare Technologies in Europe.

Keywords: health technologies,innovation,new instruments,european go-to-market strategy,competitiveness
The development of a novel therapeutic vaccine for the selective treatment of the autoimmune disorder, Graves’ disease. (DAVIAD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,Belgium,Belgium,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-12-01
End date: 2018-06-30
Duration (months): 55.0
Total project cost (EUR): 8362660.6
EU funding (EUR): 5924893.0
Participants: 4
Project status: CLOSED

This aim of the DAVIAD proposal is to develop a therapeutic vaccine for Graves’ disease (GD) that has a better safety and efficacy profile than current treatments. There is a high level of unmet need in the treatment of Graves’ disease especially in patients with Graves orbitopathy and children and adolescents (who generally suffer from the most chronic form of the disease). Autoimmune diseases arise as a consequence of a hypersensitive response to self antigens. This proposal focuses on the development of an antigen specific vaccine therapy to reinstate immune tolerance to Graves’ disease. The selected peptides behave as apitopes (antigen processing independent epitopes) and bind to MHC class II molecules in the correct confirmation to induce tolerance. In the first instance DAVIAD will further characterise antigen specific peptides (based on the autoantigen associated with the disease) already selected using a validated discovery platform. DAVIAD will generate translational data to support a clinical trial application, conduct disease model studies and prepare the clinical trial application. DAVIAD will design and conduct a phase I/IIa trial in GD patients to show that efficacy and safety compare favourably with current treatments and those in development. The consortium has the expertise required to effectively and efficiently take the proposed vaccine through clinical development and eventual commercialisation. A disease modifying vaccine for GD will address a serious unmet need and potentially offer a therapy that can change the way this disease is treated, offering better quality of life for sufferers and reducing burden on health services.

Keywords: autoimmune disease,antigen specific immunotherapy,graves disease,hyper thyroidism,immune tolerance
A Phase Ia/b study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients. (MERCURIC)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: United Kingdom,Spain,United Kingdom,Belgium,United Kingdom,Ireland,France,Italy,Czechia,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-12-01
End date: 2019-12-31
Duration (months): 73.0
Total project cost (EUR): 4552218.68
EU funding (EUR): 3458520.48
Participants: 13
Project status: CLOSED

Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omics”-based approaches, has revealed that cancer must be considered a heterogeneous disease. Historically, “one-size-fits-all” approaches have been standard practice in CRC treatment, but with the increased understanding of the molecular/genetic heterogeneity of CRC, it is clear that novel treatments must be developed and tested in selected subgroups to maximize the benefit of these new developments. MErCuRIC is a multicentre phase Ia/b clinical trial which will assess a novel therapeutic strategy (combined treatment of a MEK inhibitor PD-0325901 or MEK-162 with a MET inhibitor PF-02341066) to combat metastasis, improve survival and change current clinical practice for CRC patients with RAS mutant (MT) and RAS wild type (WT) (with aberrant c-MET) tumours. The consortium will go beyond the current state-of-the-art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next generation sequencing (NGS) and ‘xenopatients’ to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.

Keywords: multicentre clinical trial - biomarker driven - novel stratified treatment - mek/met inhibition - advanced colorectal cancer patients - combat metastases - survival - change current clinical practice
Therapeutic Beta-Lactam Monitoring for Stratified Treatment of hospital-acquired pneumonia, improved dose-dependent efficacy, decreased treatment duration, and prevention of emergence of resistance (MON4STRAT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Belgium,Belgium,France,Spain,United States,Belgium,France,Estonia,Belgium,Belgium
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-02-01
End date: 2019-07-31
Duration (months): 66.0
Total project cost (EUR): 7878841.33
EU funding (EUR): 5988941.0
Participants: 12
Project status: CLOSED

Stratified clinical treatment interventions meeting patient-specific efficacy (pharmacodynamics) while at the same time lowering the risk of emergence of drug resistance (EDR) and minimizing adverse effects are particularly needed in Hospital-acquired and Ventilator-Associated pneumonia [HAP/VAP] where morbidity, mortality and health care costs remain high. β-lactam antibiotics are at the cornerstone of most effective treatments of HAP/VAP, but dosage adaptations remain difficult because available models (i) focus mainly on efficacy (neglecting EDR and dose-related side effects) and (ii) are derived from population data which imperfectly fit individual patient’s needs due to large, rapid and difficult-to-predict variations of blood levels. Current methods for monitoring β-lactam blood levels are slow and require complex instruments not usable at bed-side. Yet, generating easily, rapidly and cost-effectively real data usable at the patient’s bed-side should improve outcomes of β-lactam treatments. This is what 3 out of the 11 partners of the MON4STRAT consortium have recently developed (patent pending). Thus the objective of the Project is to integrate both (i) state-of-the-art PK/PD and EDR profiles AND (ii) real-time/patient-specific free β-lactam blood levels monitored at the patient’s bed-side according to the patented assay for developing and implementing a new approach to (i) stratify the HAP/VAP patients according to their specific response, (ii) to propose immediately applicable dose adjustments during treatment and thus (iii) to improve efficacy while reducing risk of EDR or adverse effects. The MON4STRAT approach will be validated through a prospective, multicentre, randomized clinical trial with150 adults. Its applicability in paediatrics will be tested through an observational study with 70 children/neonates. Being generic in nature, MON4STRAT will be replicable to other infectious conditions.

Keywords: therapeutic drug monitoring,beta-lactam,hospital-acquired pneumonia,improved dose-depent efficacy,bacterial resistance,stratified treatment,emergence of drug resistance,pharmacodynamics,pk/pd
Multimodal Imaging of Neurological Disorders (MINDVIEW)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Spain,Sweden,Germany,Sweden,Spain,France,Italy,Ireland,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2018-08-31
Duration (months): 60.0
Total project cost (EUR): 6991289.4
EU funding (EUR): 5381872.0
Participants: 10
Project status: CLOSED

The key concept behind this proposal is the development of a very high resolution and high efficiency brain dedicated Positron Emission Tomograph (PET) imager that can visualize neurotransmitter pathways and their disruptions in the quest to better diagnose and consequently to better treat schizophrenia. In addition, the plan is for this compact PET imager to be integrated with a Magnetic Resonance Imager Radio Frequency (MRI RF) system to be able to operate as a brain insert in a hybrid imaging setup with practically any MRI scanner. From the technical point of view, we propose to optimize the PET technology for imaging of the human brain with the accuracy typically achieved for small animal brain imaging. To achieve this, we will incorporate the solid state based MRI-compatible PET modules that will be designed to achieve below systemic 1mm spatial resolution in a tomographic reconstruction of the human brain. We aim to achieve the level of PET-MRI compatibility allowing for simultaneous PET and MRI imaging. By combining PET measurements of neurotransmission with fMRI (functional MRI) measurements of Blood Oxygen Level Detection (BOLD) signal changes we will advance to a position where it is possible to learn more about the neurochemical determination of neural activity reflected in BOLD signal changes. The novelty is that both the PET and RF coil systems are integrated into a portable and compact design dedicated to brain examination. This will allow current MR equipment to be easily upgraded into PET/MR systems. To achieve its diagnostic goal, MINDView will be paired with the set of dedicated specific PET imaging agents and endogenous compounds that will be labeled with short-lived positron isotopes. The goal is that dopaminergic, glutamatergic and other pathways will be able to be studied with the new high performance imaging tool. Innovative paradigms such as activation and perturbation and their impact on brain function will be in focus.

Keywords: high-resolution high-sensitivity pet/mri,schizophrenia,specific radiopharmaceuticals,neurotransmitter pathways
Multidisciplinary Approaches to Translational Research In Conduct Syndromes (MATRICS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Switzerland,Italy,France,United Kingdom,Germany,United Kingdom,Netherlands,United Kingdom,Italy,Germany,France,Germany,Spain,Spain,Germany,Germany,United Kingdom
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2014-03-01
End date: 2019-11-30
Duration (months): 69.0
Total project cost (EUR): 5839093.72
EU funding (EUR): 4500000.0
Participants: 20
Project status: CLOSED

Conduct Disorder (CD) is the key paediatric disorder characterized by severe aggression. It is heterogeneous, and our understanding of the neurobiology to subtype aggression is limited. MATRICS is a multidisciplinary consortium of academic partners and SMEs that focuses on the subtyping of aggression both within CD and of the broader cross-disorder trait of aggression. MATRICS will test the hypothesis that reactive and instrumental aggression result from aberrant autonomic reactivity coupled to the differential impairment of three basic neural functions: 1) regulation of control mechanisms of aggression, 2) emotional value rating of others, and 3) empathy and moral decision making. MATRICS will employ the same psychological tasks assessing 1), 2) and 3) in animal aggression models and human CD samples concurrent with the assessment of neural, neurochemical, (epi)-genetic and autonomic nervous system markers. These data will be integrated with matching expression profiling from neurons derived from CD IPSCs. MATRICS also examines how environmental risks, whether or not they interact with genetic factors, are translated in epigenetic and neural changes. MATRICS will data-mine existing large integrated imaging-genetics cohorts (NeuroIMAGE; IMAGEN) and prospective cohorts (TRAILS; ALSPAC) with follow-up into adulthood and the (epi)genetic profiling of the PERS CD cohort, and collect a large new CD cohort and controls for collection of MRI, (epi)-genetic, biochemical and environmental measures. Bayesian machine learning tools will integrate multi-source and multi-level data, and generate predictive algorithms of persistent aggression into adulthood. MATRICS will identify new potentially ‘druggable’ targets, develop novel animal models and conduct pilot medication and neuro/biofeedback studies in high-risk and CD patients. MATRICS builds on existing fruitful EU collaborations which maximises feasibility and successful output.

Keywords: conduct disorder,control,value,empathy,autonomic nervous system,orbitofrontal cortex,anterior cingulate cortex,amygdala,insula,imaging,epigenetics,gxe,biomarker,prevention,medication
Comparing health services interventions for the prevention of HPV-related cancer (COHEAHR)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Netherlands,Spain,Finland,United Kingdom,Sweden,Belgium,Italy,France,Slovenia,Denmark,France,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-11-01
End date: 2018-10-31
Duration (months): 60.0
Total project cost (EUR): 7722783.88
EU funding (EUR): 5991528.2
Participants: 13
Project status: CLOSED

Important progress has been made in the field of HPV-disease prevention with the development and implementation of HPV vaccines and HPV DNA screening. In the CoheaHr project, the (cost-) effectiveness of different European preventive strategies will be compared. The goal is to build a reliable and comparable evidence base on the (cost-) effectiveness of these policies implemented under country-specific preventive services conditions. To achieve this goal, a set of specific tasks will be carried out. Three randomized trials will be performed in organised screening settings to determine: i) whether self-collection of specimens for HPV DNA testing is an effective and feasible alternative for physician-based sampling, ii) whether screening intervals can be extended in women vaccinated at young age, iii) whether vaccinating women two years before entering the screening programme will favour the use of HPV screening. The first and third randomized trials are multi-country trials whereas the second trial will be carried out in a cohort of Finnish women vaccinated in 2007. For unvaccinated, 25-45 year old women participating in screening, acceptability and general feasibility of HPV vaccination will be studied in a multi-country demonstration survey. Comparisons by transmission models are included to provide long-term projections for cancer incidence and mortality. Furthermore, the establishment of a standardised joint European data warehouse will be continued and extended for (continuous) evaluation of comparative effectiveness of screening and vaccination policies in Europe. Finally, there will be an ongoing effort for producing systematic reviews and meta-analyses which provide a sustainable resource for evidence. CoheaHr will provide a strong evidence base which enable policy and other decision makers to make informed decision-making on HPV prevention strategies, thereby contributing to strengthening health systems and health services interventions in Europe.

Keywords: human papillomavirus,cervical cancer,organized screening,cytology,hpv testing,vaccination,effectiveness,cost-effectiveness
Translating disease to cardiovascular health (TRANSCARD)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Denmark,Netherlands,Switzerland,France,Germany
Call:  (FP7-HEALTH-2013-INNOVATION-1, 2013)
Start date: 2013-09-01
End date: 2018-08-31
Duration (months): 60.0
Total project cost (EUR): 7627897.04
EU funding (EUR): 5884643.0
Participants: 8
Project status: CLOSED

Cardiovascular disease (CVD) is the leading cause of death in Europe and the world. Drugs that lower cholesterol in blood are the most efficient drugs used to date but we are currently still facing a 50-70% residual risk of suffering from CVD. This clearly illustrates an urgent need for the identification, characterization and validation of novel therapeutically relevant targets. Over the last decade, numerous targets have emerged but not led to successful treatment of patients. In addition to missing opportunities of health improvement beyond statins, the 92% failure rate of novel drugs also puts a large burden on the EU economy. While the causal relation between levels of lipids in plasma and CVD forms the basis of this proposal, the challenge taken up by TransCard is ‘Translating disease into Cardiovascular health’: It means that insight into the molecular origin of disturbed lipid metabolism in patients as well as the identification of lipoprotein phenotypes with causal relationships to atherosclerosis can provide immediate targets for pharmaceutical intervention leading to successful treatment of this disease. TransCard will prioritize existing and emerging targets and embark on novel unbiased approaches to identify and prioritize novel key regulators of lipid and lipoprotein metabolism. Achieving this aim will be ensured by a multidisciplinary research consortium of two SMEs and four academic partners who use innovative biotechnological and bioinformatics tools and have direct access to unique biobanks and large-scale population cohorts. This team will also help to translate the basic insight into biology into clinical use by subjecting promising targets from top level basic research to validation of their CVD association in large prospective and patient cohorts. Targets passing these tests will be studied in mice to shed further light on the feasibility of pharmaceutical intervention thereby providing lead targets for further development by other parties.

Keywords: cardiovascular disease lipids lipoproteins genetics proteomics transcriptomics